Merz Pharma GmbH & Co. KGaA
Merz Pharma GmbH & Co. KGaA, commonly referred to as Merz, is a leading global healthcare company headquartered in Frankfurt, Germany. Founded in 1908, Merz has established a strong presence in the pharmaceutical and medical aesthetics industries, focusing on innovative solutions for neurological disorders, dermatology, and aesthetic medicine. With a commitment to research and development, Merz offers a diverse portfolio of products, including the renowned Xeomin® for neuromodulation and Belotero® for dermal fillers. These offerings are distinguished by their unique formulations and efficacy, catering to both healthcare professionals and patients. Merz has achieved significant milestones, including expansion into key international markets, solidifying its position as a trusted name in the healthcare sector. The company continues to drive advancements in patient care, making it a notable player in the global pharmaceutical landscape.
DitchCarbon Score
How does Merz Pharma GmbH & Co. KGaA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Merz Pharma GmbH & Co. KGaA's score of 25 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Merz Pharma GmbH & Co. KGaA's reported carbon emissions
In 2023, Merz Pharma GmbH & Co. KGaA reported total carbon emissions of approximately 36,782,080 kg CO2e across all scopes. This includes 2,087,570 kg CO2e from Scope 1 emissions, primarily from mobile combustion, and 770,970 kg CO2e from Scope 2 emissions, mainly from purchased electricity. The company’s Scope 3 emissions were significant, totalling about 36,782,080 kg CO2e, with major contributions from purchased goods and services (27,347,590 kg CO2e) and upstream transportation and distribution (5,130,070 kg CO2e). In 2022, Merz's emissions were lower, with total emissions of approximately 44,481,120 kg CO2e, indicating a reduction in Scope 3 emissions in 2023. However, the company has not disclosed specific reduction targets or initiatives as part of its climate commitments. Merz Pharma's commitment to addressing climate change is evident through its comprehensive emissions reporting across all three scopes, although it currently lacks defined reduction targets or participation in initiatives such as the Science Based Targets initiative (SBTi). The company continues to monitor and report its carbon footprint, reflecting an awareness of its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 204,020 | 0,000,000 |
| Scope 2 | 210,110 | 000,000 |
| Scope 3 | 44,481,120 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Merz Pharma GmbH & Co. KGaA is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
